Inspirevax develops intranasal vaccines and immunotherapeutics using its proprietary Proteosome Intranasal Technology platform. This platform enables direct stimulation of mucosal immunity for less invasive delivery, with current programs targeting Alzheimer's Disease immunotherapy and an intranasal COVID-19 vaccine.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective vaccines and immunotherapeutics often faces challenges with delivery mechanisms and achieving robust mucosal immunity. Traditional methods can be invasive and may not elicit the desired immune response at key entry points for pathogens.
Solution
Inspirevax is developing novel vaccines and immunotherapeutics utilizing its proprietary Proteosome Intranasal Technology platform. This platform is designed for intranasal administration, enabling direct stimulation of mucosal immunity and offering a less invasive delivery route. The technology is being explored for both therapeutic applications and as an adjuvant to enhance the efficacy of mucosal vaccines. Current development programs focus on an immunotherapy for Alzheimer's Disease and an intranasal COVID-19 vaccine.
Target Audience
The primary target audience includes pharmaceutical companies and biotechnology firms seeking advanced platforms for vaccine and immunotherapy development, particularly those focused on infectious diseases and neurodegenerative conditions.
Features
- Proteosome Intranasal Technology platform for vaccine and immunotherapeutic development.
- Intranasal delivery system designed to stimulate mucosal immunity.
- Potential application as a therapeutic agent for neurodegenerative diseases.
- Use as an adjuvant to enhance the immunogenicity of mucosal vaccines.
- Active development programs for Alzheimer's Disease immunotherapy and an intranasal COVID-19 vaccine.